BMS and NVIDIA Unveil Game-Changing Supercomputer
July 21, 10:00 PM ET
U.S. pharmaceutical giant Bristol Myers Squibb (BMS) has announced a partnership with NVIDIA to develop what they claim will be the most advanced AI-driven supercomputer ever deployed in the drug industry. The new cluster is scheduled to go live in January 2027, promising to transform how medicines are discovered and developed. As part of the deal, BMS researchers will gain access to NVIDIA’s BioNeMo Agent Toolkit, a suite designed to dramatically boost the efficiency of their workflows.
Ongoing Collaboration and Competitive Landscape
The alliance between BMS and NVIDIA is not new—it has been active for three years. During that period, BMS already deployed its first DGX SuperPOD system, marking a major step in integrating cutting-edge technology into its operations. The upcoming supercomputer will be housed by data center operator Equinix, ensuring the infrastructure needed to run this powerful hardware.
Rivals are also moving quickly in this space. Eli Lilly bought its own equipment in October 2025, and Roche followed with a similar purchase in March 2026. However, leasing chips for computing power has proven more expensive than directly purchasing processors from NVIDIA. Moreover, reserved leased capacity only provides access to chips that are three to four generations behind, raising questions about their effectiveness compared to the latest technology.
“BMS made a deliberate bet on AI, and we are beginning to see that investment pay off across our development portfolio and operations.”
Greg Myers, Chief Digital and Technology Officer at BMS
Integrating artificial intelligence into pharmaceuticals—and building powerful computing platforms like this new BMS supercomputer—could significantly speed up the creation of new drugs. This opens up fresh possibilities for medical research, where speed and precision are critical. With competition heating up among pharmaceutical companies, such investments may prove decisive for staying ahead in the global market.